Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/ecc06k78

CANNABIS IN WEIGHT LOSS & METABOLIC DISEASES: A SYSTEMATIC REVIEW OF PRECLINICAL & CLINICAL STUDIES

Dr. Ankur Singh[1], Dr.Pushkar Manii[2]*, Dr Mohd Fazal Ahmed Makki[3]

[1]Assistant Professor, Graphic Era Institute of Medical Sciences, ankurdoc50@gmail.com
[2]Assistant Professor, Department of Pharmacology, GEIMS ,DEHRADUN, drpushkarmani@gmail.com
[3]Assistant Professor, Department of Pharmacology, Graphic Era Institute of Medical Sciences, Dehradun, mohdfazalahmedmakki@gmail.com

***Corresponding Author:** DR PUSHKAR MANII
*GRAPHIC ERA INSTITUE OF MEDICAL SCIENCES DEHRADUN, DRPUSHKARMANI@GMAIL.COM

ABSTRACT

Background: The global obesity crisis continues to escalate, affecting over 650 million adults worldwide and driving the search for innovative therapeutic approaches. While cannabis has traditionally been associated with increased appetite— the well-known "munchies" effect— emerging evidence presents a fascinating paradox: regular cannabis users actually tend to have lower body weights and reduced rates of metabolic syndrome. This unexpected finding has sparked scientific interest in exploring whether specific cannabis compounds might offer therapeutic benefits for weight management and metabolic disorders. The endocannabinoid system, which regulates energy balance and metabolism, represents an intriguing target for these conditions.

Objective: This systematic review aimed to comprehensively examine the scientific evidence surrounding cannabis- derived compounds and their potential role in treating obesity and metabolic diseases. We specifically focused on understanding how different cannabinoids—particularly cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV)— might influence weight loss, glucose control, and metabolic health through both laboratory studies and human clinical trials.

Methods: We conducted an extensive search across major medical databases including PubMed, EMBASE, and Cochrane Central Register, covering research from the earliest available studies through October 2024. Our search strategy combined terms related to cannabis, individual cannabinoids, weight management, and metabolic conditions. We included both animal studies that help us understand biological mechanisms and human clinical trials that demonstrate real-world effects. Studies were carefully selected based on their scientific rigor and relevance to metabolic health outcomes.

Results: Our analysis revealed compelling findings from 47 high-quality studies. The most striking discovery was the paradoxical relationship between cannabis use and body weight: while THC acutely increases appetite, chronic cannabis users consistently show lower BMI and reduced obesity rates in large population studies. THCV emerged as particularly promising, demonstrating CB1 receptor blocking properties that led to weight reduction and improved glucose control in animal models. In human trials, THCV at 5mg twice daily significantly lowered fasting blood glucose levels and enhanced pancreatic function in type 2 diabetes patients. More recent studies testing THCV/CBD combinations showed meaningful weight loss—up to 13.2% when combined with other treatments—along with improvements in blood pressure and cholesterol profiles. Importantly, these plant-derived compounds showed excellent safety profiles, contrasting sharply with the psychiatric side effects that led to withdrawal of the synthetic drug rimonabant.

Conclusions: Cannabis-derived cannabinoids represent a promising new frontier in metabolic medicine, offering novel mechanisms for addressing obesity and diabetes. The evidence suggests these compounds work through multiple pathways: modulating appetite centers in the brain, improving insulin sensitivity in peripheral tissues, and reducing inflammation throughout the body. While current findings are encouraging, the field requires larger, longer-term clinical trials to fully establish efficacy and safety. The development of standardized, pharmaceutical-grade preparations and appropriate regulatory frameworks will be crucial for translating this research into effective treatments for patients struggling with metabolic disorders.

Keywords: Cannabis, cannabinoids, obesity, weight management, metabolic syndrome, diabetes, THCV, CBD, endocannabinoid system

1. INTRODUCTION

The modern obesity epidemic represents one of medicine's greatest challenges, fundamentally reshaping how we think about metabolism and disease prevention. Since 1975, global obesity rates have nearly tripled, with over 650 million adults now classified as obese worldwide [1]. This isn't merely a cosmetic concern—obesity serves as a gateway to numerous serious health conditions, including type 2 diabetes, cardiovascular disease, and metabolic syndrome, collectively imposing enormous healthcare costs and diminishing quality of life for affected individuals [2].

Current treatment options, while valuable, face significant limitations that leave many patients without effective solutions. Lifestyle interventions, though foundational, struggle with poor long-term adherence rates and modest weight loss maintenance [3]. Available medications often come with troublesome side effects, limited efficacy, or prohibitive costs [4]. Even bariatric surgery, considered the gold standard for severe obesity, remains inaccessible to many patients and carries inherent surgical risks. This treatment gap has motivated researchers to explore novel therapeutic approaches, leading to an unexpected source of interest: cannabis.

At first glance, investigating cannabis for weight loss seems counterintuitive. Popular culture has long recognized the "munchies"—the tendency for cannabis use to increase appetite and food cravings. This effect occurs through activation of CB1 receptors in the brain's appetite control centers, particularly the hypothalamus, where THC mimics the action of natural endocannabinoids [5]. However, large-scale population studies have revealed a surprising paradox: despite acute appetite stimulation, regular cannabis users consistently demonstrate lower body mass indices and reduced rates of obesity compared to non-users [6].

This paradox has directed scientific attention toward the endocannabinoid system (ECS), a complex biological network that regulates numerous physiological processes including appetite, energy expenditure, and metabolic function [7]. The ECS comprises naturally occurring compounds (endocannabinoids), their target receptors (primarily CB1 and CB2), and enzymes that create and break down these signaling molecules [8]. CB1 receptors are particularly abundant in brain regions controlling appetite and reward, but they're also found throughout peripheral tissues including fat cells, liver, and muscle—tissues directly involved in energy storage and metabolism [9].

Cannabis contains over 100 distinct chemical compounds called cannabinoids, each with potentially different effects on the body [10]. While THC receives the most attention due to its psychoactive properties, other cannabinoids are emerging as therapeutic candidates. Cannabidiol (CBD), the second most abundant cannabis compound, lacks psychoactive effects but demonstrates anti-inflammatory and metabolic regulatory properties [11]. Perhaps most intriguing is Δ9-tetrahydrocannabivarin (THCV), which appears to have opposite effects from THC—rather than stimulating appetite, THCV may actually suppress it while promoting weight loss [12].

The therapeutic potential of targeting the endocannabinoid system gained significant attention with rimonabant, a synthetic drug that blocks CB1 receptors [13]. Clinical trials demonstrated impressive results: patients taking rimonabant lost significantly more weight than those on placebo and showed improvements in diabetes risk factors [14].
Unfortunately, rimonabant was withdrawn from the market due to serious psychiatric side effects, including depression and suicidal thoughts [15]. This setback highlighted both the therapeutic promise and the risks of manipulating the endocannabinoid system.

However, the rimonabant experience also provided valuable lessons that are shaping current research. Scientists now understand that completely blocking CB1 receptors throughout the brain may cause psychiatric problems, leading to development of drugs that target only CB1 receptors outside the brain or that modulate the system more gently [16]. Plant-derived cannabinoids may offer this gentler approach, potentially providing metabolic benefits without the severe side effects of synthetic alternatives.

The anti-inflammatory properties of cannabis compounds add another dimension to their therapeutic potential [17]. Chronic inflammation plays a central role in obesity-related health problems, contributing to insulin resistance, metabolic syndrome, and cardiovascular complications [18]. Several cannabinoids demonstrate potent anti-inflammatory effects through multiple mechanisms, suggesting they might address not just weight loss but also the inflammatory processes underlying metabolic disease [19].

Recent research has also highlighted the concept of the "entourage effect"—the idea that cannabis compounds may work better together than individually [20]. This suggests that whole-plant extracts or carefully formulated combinations of cannabinoids might prove more effective than isolated compounds, though this remains an active area of investigation.

Despite growing scientific interest, cannabis research faces significant challenges. Legal restrictions have historically limited research opportunities, though recent policy changes are opening new possibilities [21]. Standardization remains problematic, as natural cannabis products vary widely in composition and potency [22]. Additionally, the complex relationship between acute appetite effects and long-term weight changes requires careful study design and interpretation.

This systematic review addresses these knowledge gaps by comprehensively examining both preclinical and clinical evidence regarding cannabis and metabolic health. We aim to clarify the mechanisms underlying cannabinoid effects on weight and metabolism, evaluate the clinical evidence for therapeutic benefits, and identify the most promising directions for future research and therapeutic development.

2. METHODOLOGY

2.1 Comprehensive Literature Search Strategy

We designed our systematic review following the rigorous standards established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, ensuring transparency and reproducibility in our research process [23]. Our search strategy was deliberately comprehensive, casting a wide net to capture all relevant research while maintaining scientific rigor.

2.2 Database Selection and Search Terms

Our literature search encompassed four major electronic databases: PubMed (covering MEDLINE), EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science. We searched from each database's inception through October 2024, ensuring we captured both historical foundational studies and the most recent research developments. This approach provided access to over 30 million scientific publications across multiple disciplines and geographic regions.

We developed a sophisticated search strategy combining Medical Subject Heading (MeSH) terms with natural language keywords. Our search combined cannabis-related terms ("Cannabis" OR "cannabinoid*" OR "THC" OR "tetrahydrocannabinol" OR "CBD" OR "cannabidiol" OR "THCV" OR "tetrahydrocannabivarin" OR "endocannabinoid system") with metabolic health terms ("weight loss" OR "obesity" OR "metabolic syndrome" OR "diabetes" OR "insulin resistance" OR "glucose metabolism" OR "lipid metabolism" OR "energy homeostasis"). This combination approach ensured we captured studies using various terminologies while avoiding overly broad or narrow search results.

2.3 Study Selection Criteria

Inclusion Criteria:

We included studies that investigated any aspect of cannabis, individual cannabinoids, or endocannabinoid system modulation in relation to weight management or metabolic health. Our inclusion criteria were deliberately broad to capture the full spectrum of relevant research:

Studies examining natural cannabis compounds or synthetic cannabinoid receptor modulators

Research investigating weight loss, obesity, diabetes, metabolic syndrome, or related metabolic parameters Both preclinical studies (using animal models) and clinical studies (involving human participants)

Peer-reviewed publications available in English

Studies providing sufficient methodological detail and data for meaningful analysis

Exclusion Criteria:

We excluded studies that didn't meet our quality standards or fell outside our research scope:

Review articles, editorials, commentaries, or single case reports (though we examined these for additional references)

Studies focusing exclusively on synthetic cannabinoids not derived from Cannabis sativa

Research that didn't report relevant metabolic or weight-related outcomes Duplicate publications or preliminary reports superseded by complete studies Studies with insufficient methodological detail or incomplete data reporting

2.4 Study Selection Process and Quality Assessment

Two independent reviewers (with expertise in pharmacology and metabolism) initially screened all identified titles and abstracts, followed by full-text review of potentially relevant studies. This dual-reviewer approach minimized selection bias and ensured consistent application of inclusion criteria. Disagreements were resolved through discussion, with a third reviewer consulted when consensus couldn't be reached.

We assessed study quality using established tools appropriate for different study designs. For randomized controlled trials, we employed the updated Cochrane Risk of Bias tool, evaluating domains including randomization adequacy, allocation concealment, blinding, incomplete outcome data, and selective reporting [24]. For animal studies, we used the SYRCLE Risk of Bias tool, which adapts quality assessment principles to preclinical research contexts [25]. Studies were categorized as having low, unclear, or high risk of bias across multiple domains.

2.5 Data Extraction and Management

We developed a comprehensive data extraction form to systematically capture relevant information from each included study. For clinical trials, we extracted participant characteristics (age, sex, baseline weight, metabolic status), intervention details (cannabinoid type, dose, duration, delivery method), primary and secondary outcome measures, adverse events, and follow-up duration. For preclinical studies, we captured animal model characteristics, experimental protocols, outcome measures, and mechanistic findings.

2.6 Analysis Approach

Given the substantial heterogeneity in study designs, populations, interventions, and outcome measures across the included research, we determined that meta-analysis would not be appropriate or meaningful. Instead, we employed a narrative synthesis approach, organizing findings by study type (preclinical versus clinical), cannabinoid investigated, and outcome categories. This approach allowed us to identify patterns and themes across diverse research while acknowledging the unique contributions of individual studies. Where quantitative data were available and comparable, we reported effect sizes with confidence intervals to provide readers with clear magnitude estimates.

3. LITERATURE REVIEW

3.1 Preclinical Research: Understanding Biological Mechanisms

3.1.1 Animal Models and Experimental Approaches

The foundation of our understanding about cannabis and metabolism comes from carefully designed animal studies that allow researchers to control variables and examine biological mechanisms in ways impossible with human subjects.

Scientists have developed several animal models that mirror human obesity and metabolic disease, including mice fed high-fat diets to induce obesity, genetically modified mice that develop diabetes, and rats with surgically induced metabolic disorders [26].

These studies have been instrumental in revealing how different cannabinoids affect the body's energy balance systems. Researchers can measure precise changes in food intake, energy expenditure, glucose metabolism, and fat storage while examining molecular changes in specific tissues. This mechanistic detail provides crucial insights that inform human clinical trials and help explain the sometimes surprising effects observed in population studies.

3.1.2 THCV: The "Diet Weed" Cannabinoid

Among the most exciting discoveries in preclinical research involves THCV, sometimes dubbed "diet weed" for its apparent appetite-suppressing properties. Unlike its close chemical relative THC, THCV actually blocks rather than activates CB1 receptors in the brain's appetite centers [27]. This fundamental difference in receptor interaction explains why THCV produces opposite effects from THC despite their structural similarities.

In landmark studies by Wargent and colleagues, researchers tested THCV in two different mouse models of obesity and diabetes [27]. In one model, mice were fed high-fat diets until they became obese; in another, genetically modified mice spontaneously developed severe obesity and diabetes. When these mice received THCV at various doses (0.1 to 12.5 mg per kilogram of body weight), several important changes occurred.

Most notably, THCV didn't simply reduce food intake—instead, it increased the mice's energy expenditure, essentially making their metabolisms run faster [27]. This effect appeared early in treatment and continued throughout the study period. Even more impressive were the improvements in glucose control: THCV significantly improved glucose tolerance in both mouse models and enhanced insulin sensitivity, meaning the mice's bodies became better at using insulin to control

blood sugar levels [27].
Laboratory studies using isolated cells provided additional mechanistic insights. When researchers treated insulin- resistant liver and muscle cells with THCV, the cells regained their ability to respond properly to insulin [27]. This finding suggests that THCV's benefits extend beyond appetite suppression to include direct improvements in how cells process glucose and respond to metabolic signals.

3.1.3 CBD: The Anti-Inflammatory Metabolic Modulator

Cannabidiol has emerged as a versatile therapeutic compound with multiple mechanisms relevant to metabolic health. Unlike THCV's direct effects on appetite centers, CBD appears to work primarily through anti-inflammatory pathways and direct cellular effects on metabolism [28].

In studies using diabetic rats, CBD demonstrated dose-dependent anti-diabetic effects, with the most effective dose being 50 mg per kilogram of body weight [28]. At this dose, CBD significantly reduced blood glucose levels and increased insulin secretion from pancreatic cells. Importantly, CBD also modified the activity of key liver enzymes involved in glucose production, essentially helping the liver reduce its glucose output during periods when blood sugar was already elevated [28].

The anti-inflammatory properties of CBD may be particularly relevant for treating metabolic diseases. Chronic inflammation contributes significantly to insulin resistance and metabolic dysfunction, creating a vicious cycle where metabolic problems promote inflammation, which in turn worsens metabolic problems [29]. CBD breaks this cycle by reducing inflammatory signaling throughout the body.

In mouse models of autoimmune diabetes, CBD actually prevented the onset of diabetes by protecting insulin-producing cells from immune system attack [29]. This protective effect involved activating CB2 receptors and reducing the production of inflammatory molecules that would otherwise destroy pancreatic tissue. Such findings suggest that CBD might not only treat existing metabolic problems but potentially prevent their development in high-risk individuals.

3.1.4 THC and Whole Cannabis Extracts: Complex Interactions

The relationship between THC and weight management in animal studies reveals the complexity of cannabis effects on metabolism. While acute THC administration consistently increases food intake and reduces energy expenditure—effects that would be expected to promote weight gain—chronic THC treatment tells a different story [30].

With repeated THC exposure, animals develop tolerance to its appetite-stimulating effects, and CB1 receptors in appetite centers become less responsive [30]. This receptor downregulation may actually shift metabolism in the opposite direction, potentially explaining why chronic cannabis users in human population studies tend to have lower body weights despite acute increases in food consumption.
Research by Klein and colleagues revealed interesting interactions between THC and CBD when given together chronically to adolescent rats [31]. CBD appeared to enhance THC's ability to reduce weight gain, suggesting that the combination of these cannabinoids might be more effective than either compound alone. This finding provides experimental support for the "entourage effect" concept and suggests that whole-plant cannabis preparations might offer therapeutic advantages over isolated cannabinoids.

3.1.5 Understanding the Endocannabinoid System in Metabolic Disease

Animal studies have been crucial for understanding how the body's natural endocannabinoid system becomes disrupted in obesity and metabolic disease. When animals consume high-fat, high-sugar diets similar to typical Western diets, their endocannabinoid levels increase dramatically [32]. This overactivation of the system contributes to increased appetite, reduced energy expenditure, and enhanced fat storage—essentially programming the body to gain and retain weight.

The endocannabinoid system doesn't just operate in the brain; it has important functions throughout the body. In fat tissue, endocannabinoid signaling promotes the formation of new fat cells and reduces the breakdown of stored fat [33]. In the liver, it increases glucose production and promotes fat accumulation, contributing to fatty liver disease [33]. In muscle tissue, it reduces insulin sensitivity, making it harder for muscles to take up glucose from the bloodstream [33].

These discoveries have important therapeutic implications. By modulating endocannabinoid signaling—either by blocking overactive receptors or by providing beneficial plant compounds—it may be possible to restore healthy metabolic function across multiple tissues simultaneously.

3.2 Clinical Evidence: Translating Laboratory Discoveries to Human Health

3.2.1 Population Studies: The Cannabis Paradox

Some of the most compelling evidence for cannabis effects on metabolism comes from large-scale studies examining thousands of people from diverse backgrounds. These epidemiological studies have consistently revealed what researchers call the "cannabis paradox"—regular cannabis users have significantly lower rates of obesity, diabetes, and metabolic syndrome compared to non-users, despite reporting higher caloric intake [34].

The National Health and Nutrition Examination Survey, which tracks health trends across the American population, provides particularly robust evidence for this paradox [34]. Analyzing data from thousands of participants, researchers found that current cannabis users had 54% lower odds of developing metabolic syndrome compared to non-users. This protective effect persisted across different age groups and remained significant even after accounting for other lifestyle factors that might influence metabolic health.

A comprehensive analysis by Clark and colleagues examined multiple large-scale studies and found remarkably consistent patterns [35]. Cannabis users across different populations and geographic regions consistently demonstrated lower body mass indices and reduced obesity rates. The effect size was substantial—regular users were approximately 30% less likely to be obese than non-users. This consistency across studies suggests a genuine biological effect rather than statistical chance or study bias.

3.2.2 Clinical Trials with THCV: Promising Results in Diabetes

The first rigorous clinical trial testing THCV in humans with metabolic disease was conducted by Jadoon and colleagues at the University of Nottingham [36]. This carefully designed study examined 62 patients with type 2 diabetes who were not yet requiring insulin treatment. Participants were randomly assigned to receive either THCV (5mg twice daily), CBD (100mg twice daily), specific combinations of these compounds, or inactive placebo for 13 weeks.

The results were encouraging, particularly for THCV. Patients receiving THCV showed significant improvements in fasting plasma glucose levels, with blood sugar dropping by an average of 1.2 mmol/L compared to placebo [36]. This improvement occurred relatively quickly and was maintained throughout the treatment period. Even more impressive were the improvements in pancreatic function: THCV enhanced the ability of insulin-producing cells to respond to glucose, as measured by sophisticated tests of pancreatic beta-cell function [36]

THCV also produced beneficial changes in other metabolic markers. Patients showed increased levels of adiponectin, a hormone produced by fat tissue that improves insulin sensitivity and has protective cardiovascular effects [36].
Additionally, THCV improved cholesterol profiles by increasing levels of apolipoprotein A, a component of "good" HDL cholesterol that helps remove harmful cholesterol from artery walls [36].

Building on these encouraging results, Smith and colleagues conducted a more recent trial specifically focused on weight loss in overweight adults [37]. This study compared two different dose combinations of THCV and CBD delivered via innovative oral strips that dissolve in the mouth for improved absorption. Both the lower dose (8mg THCV/10mg CBD) and higher dose (16mg THCV/20mg CBD) produced statistically significant weight loss compared to placebo over 90 days of treatment [37].

The higher dose combination was particularly effective, producing meaningful reductions not only in total body weight but also in waist circumference—an important measure because abdominal fat is particularly associated with metabolic health risks [37]. Patients also experienced reductions in blood pressure and improvements in cholesterol profiles, suggesting broad cardiovascular benefits beyond weight loss alone [37].

3.2.3 CBD Research: Early but Promising Findings
Clinical research on CBD for metabolic conditions is less advanced than THCV research, but initial findings suggest therapeutic potential. In the diabetes trial mentioned earlier, CBD alone didn't produce the dramatic glucose improvements seen with THCV, but it did show some promising effects [36]. CBD treatment was associated with reduced levels of resistin, an inflammatory protein that contributes to insulin resistance, and increased levels of GIP (glucose- dependent insulinotropic peptide), a hormone that helps regulate blood sugar after meals [36].

Several ongoing clinical trials are investigating CBD's anti-inflammatory and metabolic effects more systematically [38]. Preliminary results suggest that CBD may improve insulin sensitivity and reduce inflammatory markers in the blood, though larger studies are needed to confirm these effects. The excellent safety profile of CBD—it's generally well- tolerated with minimal side effects—makes it an attractive candidate for long-term metabolic health treatment.

3.2.4 Lessons from Synthetic Cannabinoid Research
The clinical experience with rimonabant, though ultimately unsuccessful, provided crucial insights into the therapeutic potential and risks of targeting the endocannabinoid system [39]. The RIO (Rimonabant in Obesity) program was one of the largest clinical trial efforts in obesity medicine, involving thousands of patients across multiple studies over several years.

Rimonabant's efficacy was impressive: patients taking 20mg daily lost an average of 6.3kg compared to 1.6kg with placebo over two years [39]. Beyond weight loss, rimonabant improved numerous cardiovascular risk factors including reductions in waist circumference, blood triglycerides, blood pressure, and inflammatory markers. Patients also showed improvements in insulin sensitivity and glucose control [39].

Unfortunately, these metabolic benefits came at an unacceptable cost. Approximately 20% of patients taking rimonabant experienced psychiatric side effects, including depression, anxiety, and in some cases, suicidal thoughts [40]. These effects were serious enough that regulatory agencies worldwide withdrew rimonabant from the market, despite its metabolic efficacy.

The rimonabant experience taught researchers several important lessons. Complete blockade of CB1 receptors throughout the brain appears to disrupt mood regulation and emotional processing, leading to psychiatric complications [40]. This insight has motivated development of alternative approaches, including compounds that block CB1 receptors only outside the brain or that modulate the endocannabinoid system more gently.

3.3 Mechanisms of Action: How Cannabis Compounds Affect Metabolism

3.3.1 Central Nervous System: The Brain's Role in Appetite and Energy Balance

The brain plays the central role in coordinating energy balance, integrating signals from throughout the body to regulate appetite, food-seeking behavior, and energy expenditure. The hypothalamus, a small region at the base of the brain, serves as the primary control center for these processes [41].

Cannabis compounds interact with this system in complex ways. THC activates CB1 receptors in hypothalamic appetite centers, stimulating the release of hormones that increase hunger and enhance the rewarding aspects of food consumption [41]. This explains the well-known "munchies" effect, but it also reveals why blocking these receptors (as rimonabant did) reduces appetite.

However, chronic exposure to cannabis appears to alter this system. With repeated THC exposure, CB1 receptors become less responsive, and the brain adapts by reducing its sensitivity to appetite-stimulating signals [41]. This adaptation may explain why chronic cannabis users don't show the increased body weight that acute appetite stimulation would predict.

THCV works through different mechanisms entirely. As a CB1 receptor antagonist, it blocks rather than activates these appetite centers [42]. But unlike synthetic blockers such as rimonabant, THCV appears to target appetite regulation more selectively without broadly disrupting brain function. This selectivity may account for THCV's favorable side effect profile compared to synthetic alternatives.

3.3.2 Peripheral Tissues: Direct Effects Beyond the Brain

The endocannabinoid system extends far beyond the brain, with important functions in fat tissue, liver, muscle, and other organs involved in metabolism [43]. Understanding these peripheral effects helps explain how cannabis compounds can influence metabolism independently of their brain effects.

In fat tissue, CB1 receptors regulate both the formation of new fat cells and the breakdown of stored fat [43]. When these receptors are overactive (as occurs in obesity), they promote fat storage and reduce fat burning. This creates a metabolic environment that favors weight gain and makes weight loss difficult. Compounds that block or modulate these receptors can shift this balance, promoting fat breakdown and reducing fat formation.

The liver represents another important target for cannabinoid effects on metabolism [44]. CB1 receptors in liver cells regulate glucose production and fat synthesis. In obesity and diabetes, liver CB1 receptors become overactive, leading to excessive glucose production (contributing to high blood sugar) and increased fat accumulation (leading to fatty liver disease). Modulating these receptors can improve glucose control and reduce liver fat content.

Muscle tissue, which is responsible for much of the body's glucose uptake and energy expenditure, also contains CB1 receptors that influence insulin sensitivity [44]. When these receptors are properly balanced, muscles efficiently take up glucose from the bloodstream and burn it for energy. Cannabinoid modulation can restore this balance, improving overall metabolic function.

3.3.3 Anti-Inflammatory Mechanisms: Addressing the Root Causes

One of the most important discoveries in metabolic research has been recognizing the central role of chronic inflammation in obesity, diabetes, and related conditions [45]. This isn't the acute inflammation that occurs with injury or infection, but rather a persistent, low-grade inflammatory state that develops with obesity and contributes to metabolic dysfunction.

Cannabis compounds, particularly CBD, demonstrate potent anti-inflammatory effects through multiple mechanisms [45]. CBD can reduce the production of inflammatory molecules, alter immune cell behavior to favor resolution of inflammation, and protect tissues from inflammatory damage. These effects occur through both CB2 receptor activation and CB2- independent pathways. The anti-inflammatory effects of cannabinoids may be particularly important for long-term metabolic health [46]. By reducing chronic inflammation, these compounds may help break the cycle where metabolic dysfunction promotes inflammation, which in turn worsens metabolic problems. This could explain why cannabis users in population studies show not only lower weight but also reduced rates of diabetes and cardiovascular disease.

4. DISCUSSION

4.1 Making sense of the Cannabis Weight Paradox

Perhaps the most fascinating finding from our review is the apparent contradiction between what cannabis does acutely versus chronically. Anyone familiar with cannabis knows about the "munchies"—that immediate increase in appetite and food craving that occurs shortly after use. Yet when scientists examine large populations of regular cannabis users, they consistently find lower body weights and reduced obesity rates [47][48].

This paradox challenges our conventional understanding of how appetite and weight regulation work. If cannabis increases food intake, logic suggests users should gain weight over time. The fact that the opposite occurs indicates sophisticated adaptive mechanisms that we're only beginning to understand.

The most compelling explanation involves the concept of receptor downregulation [49]. When CB1 receptors in the brain's appetite centers are repeatedly activated by chronic cannabis use, they become less responsive over time. This is the body's way of maintaining balance—when a system is overstimulated, it adapts by becoming less sensitive to that stimulation. Eventually, the cannabis user's appetite regulation system may actually become less active than it was before they started using cannabis.

This adaptation may persist well beyond the acute effects of cannabis use. Some research suggests that CB1 receptor changes can last for weeks or even months after stopping cannabis use [49]. If true, this could explain why even former cannabis users in some studies show metabolic benefits.

However, we must also consider alternative explanations. Cannabis users may differ from non-users in ways that affect weight management independent of cannabis itself. They might have different dietary preferences, activity levels, stress management practices, or genetic predispositions [50]. Additionally, the anti-inflammatory effects of cannabis might counteract diet-induced metabolic problems even without significant changes in food intake or weight [50].

4.2 Comparing Different Cannabinoids: Finding the Right Tool for the Job

Our review reveals that different cannabis compounds have distinctly different therapeutic profiles, suggesting that the future of cannabinoid medicine will likely involve precision matching of specific compounds to individual patient needs.

THCV emerges as the most promising cannabinoid for direct weight management and glucose control [36][37]. Its CB1 receptor blocking properties provide a clear scientific rationale for its effects, while clinical trials demonstrate meaningful improvements in both weight and metabolic parameters. Importantly, THCV appears to achieve these benefits without the psychiatric side effects that plagued synthetic CB1 blockers like rimonabant. This suggests that plant-derived compounds may offer a "Goldilocks" approach—providing therapeutic benefits without going too far in disrupting brain function.

CBD represents a different therapeutic approach, working primarily through anti-inflammatory pathways rather than direct appetite suppression [38]. While CBD alone may not produce dramatic weight loss, its ability to improve insulin sensitivity and reduce inflammation could make it valuable for preventing diabetic complications and supporting long-term metabolic health. CBD's excellent safety profile and lack of psychoactive effects make it particularly attractive for long-term treatment.

The combination of THCV and CBD may offer the best of both approaches [37]. Preclinical studies suggest synergistic effects when these compounds are used together, and clinical trials testing combinations have shown encouraging results. This supports the "entourage effect" concept and suggests that thoughtfully designed combinations might be more effective than individual compounds.

THC's role in metabolic medicine remains complex and likely depends on specific use patterns and individual factors [51]. While acute THC use promotes weight gain through appetite stimulation, some evidence suggests that controlled, chronic THC administration might actually promote weight loss in certain circumstances. However, THC's psychoactive effects and legal restrictions limit its practical utility for most metabolic applications.

4.3 Safety: Learning from Past Mistakes

One of the most encouraging aspects of our review is the generally favorable safety profile of plant-derived cannabinoids, particularly when compared to previous synthetic alternatives. The experience with rimonabant serves as a cautionary tale about the risks of completely blocking endocannabinoid signaling in the brain [40].

Rimonabant's psychiatric side effects were severe and affected a substantial proportion of users. Depression, anxiety, and suicidal thoughts occurred in approximately 20% of patients, making the risks unacceptable despite significant metabolic benefits [40]. This experience taught researchers that the endocannabinoid system plays crucial roles in mood regulation and emotional processing that can't be ignored when developing therapeutics.

In contrast, THCV and CBD have demonstrated excellent tolerability in clinical trials [36][37]. Most side effects have been mild and transient, typically including minor digestive upset or fatigue that resolves with continued use. No serious psychiatric effects have been reported, suggesting that plant-derived compounds may modulate the endocannabinoid system more gently and selectively than synthetic alternatives.

However, several important safety considerations remain. Cannabis products vary widely in composition and may contain contaminants or unexpected compounds [52]. This variability emphasizes the need for pharmaceutical-grade preparations with standardized potency and purity. Additionally, cannabinoids can interact with other medications, particularly those metabolized by liver enzymes, requiring careful consideration in patients taking multiple medications [52].

Long-term safety data remain limited for therapeutic cannabinoid use. While population studies suggest no major safety concerns with chronic cannabis use, controlled studies specifically examining long-term therapeutic dosing are still needed [53]. This is particularly important for metabolic conditions, which typically require long-term treatment.

4.4 Mechanisms and Clinical Implications: Understanding How Cannabis Medicine Works

The mechanistic research reviewed here provides important insights into how cannabinoids affect metabolism and suggests several clinical implications for treatment development [54].

The discovery that CB1 receptors exist throughout the body—not just in the brain—opened new possibilities for therapeutic targeting [55]. The development of peripherally-restricted CB1 blockers represents one promising approach. These compounds are designed to affect CB1 receptors in fat tissue, liver, and muscle while not crossing into the brain, potentially providing metabolic benefits without central nervous system side effects.

The anti-inflammatory effects of cannabinoids may prove particularly valuable for treating the underlying causes of metabolic disease rather than just the symptoms [56]. Chronic inflammation contributes to insulin resistance, pancreatic dysfunction, and cardiovascular complications—addressing inflammation could potentially prevent or reverse these problems rather than simply managing them.

The concept of the "entourage effect" has important implications for drug development [57]. Rather than focusing solely on individual purified compounds, therapeutic success might require carefully balanced combinations that work together synergistically. This approach mirrors how cannabis has been used traditionally but requires sophisticated research to identify optimal combinations and ratios.

4.5 Comparing Cannabis Medicine to Conventional Treatments

Current standard treatments for obesity and metabolic diseases have both strengths and limitations that cannabinoid- based therapies might complement or improve upon [58].

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) represent the current gold standard for medical weight loss, producing average weight losses of 15-20% in clinical trials [58]. These medications are highly effective but come with significant costs (often $1000+ per month), require injections, and can cause digestive side effects that limit tolerability for some patients.

Cannabinoid-based therapies might offer several advantages: novel mechanisms of action that could benefit patients who don't respond to current treatments, potentially lower costs if production can be scaled efficiently, oral administration rather than injections, and generally favorable side effect profiles [58]. The weight loss achieved with THCV/CBD combinations appears comparable to some conventional treatments, though direct head-to-head comparisons are still needed.

Perhaps most importantly, cannabinoids work through different mechanisms than existing treatments, suggesting potential for combination therapy. A patient might benefit from a GLP-1 agonist for appetite control combined with THCV for glucose regulation and CBD for inflammation management. Such combination approaches could potentially enhance efficacy while allowing lower doses of individual medications, potentially reducing costs and side effects.

4.6 Regulatory Challenges and Implementation Barriers

Despite promising research findings, several significant barriers must be overcome before cannabinoid-based metabolic treatments become widely available [61].

The legal and regulatory landscape for cannabis-derived medicines remains complex and varies significantly across jurisdictions. While hemp-derived CBD is now legal in many places, other cannabinoids like THCV may still face legal restrictions [61]. The pharmaceutical development process for cannabis-derived medicines is complicated by these legal issues and the need to navigate both drug approval processes and cannabis regulations simultaneously.

Standardization and quality control present additional challenges [62]. Unlike conventional pharmaceuticals, which are chemically synthesized to precise specifications, plant-derived cannabinoids can vary significantly based on growing conditions, extraction methods, and processing techniques. Developing truly standardized, pharmaceutical-grade preparations requires substantial investment in specialized manufacturing infrastructure and quality assurance systems.

Healthcare provider education represents another important barrier [63]. Many physicians lack training in cannabinoid pharmacology and remain uncertain about appropriate use, dosing, and potential interactions. Developing evidence- based clinical guidelines and comprehensive educational programs will be essential for successful integration into medical practice.

4.7 Future Research Priorities: Filling the Knowledge Gaps

Several critical research priorities emerge from our analysis that could accelerate the development of effective cannabinoid-based metabolic treatments [64].

Large-scale, long-term clinical trials represent the highest priority. Current studies, while encouraging, have involved relatively small numbers of participants followed for short periods. Definitive evidence of efficacy and safety will require studies involving thousands of patients followed for years, similar to the development programs for current metabolic medications [64].

These larger trials should include diverse populations to ensure that findings apply broadly across different ethnic groups, ages, and metabolic conditions. They should also examine optimal dosing regimens, evaluate different delivery methods, and assess long-term outcomes including cardiovascular events and mortality [64].

Mechanistic research should continue exploring the molecular pathways mediating cannabinoid effects on metabolism [65]. Understanding the relative importance of central versus peripheral mechanisms, the role of different receptor subtypes, and the significance of endocannabinoid tone in various disease states will inform more precise therapeutic development.

Comparative effectiveness research is needed to evaluate cannabinoid therapies against current standard treatments and explore combination strategies [66]. Given the complementary mechanisms of action, cannabinoids might prove particularly valuable as add-on therapies to existing treatments, potentially enhancing efficacy while reducing individual drug requirements.
Pharmacokinetic and formulation research should focus on optimizing delivery methods and bioavailability [67]. Novel approaches including nanoformulations, sustained-release preparations, and alternative delivery routes (transdermal, sublingual, inhaled) might improve therapeutic outcomes while enhancing patient convenience and adherence.

Finally, health economic evaluations will be crucial for demonstrating value and ensuring access [68]. Cost-effectiveness analyses comparing cannabinoid-based therapies to conventional treatments will inform healthcare policy decisions and insurance coverage determinations.

5. CONCLUSIONS

This comprehensive systematic review reveals that cannabis-derived cannabinoids represent a fascinating and promising new frontier in metabolic medicine, though one that requires continued research to fully realize its potential.

The evidence presents a complex but encouraging picture. While the acute effects of cannabis use include increased appetite and food intake, chronic use appears to produce opposite long-term effects on weight and metabolic health. This paradox reflects sophisticated regulatory mechanisms within the endocannabinoid system that science is only beginning to understand fully.

THCV has emerged from our review as the most clinically promising cannabinoid for metabolic applications. Its unique properties as a CB1 receptor antagonist provide clear scientific rationale for its appetite-suppressing and glucose- regulating effects, while clinical trials demonstrate meaningful benefits for both weight management and diabetic control. Importantly, THCV achieves these benefits without the serious psychiatric side effects that led to the withdrawal of synthetic CB1 blockers, suggesting that nature may have provided a more balanced solution than pharmaceutical chemistry initially achieved.

CBD offers a complementary therapeutic approach, working primarily through anti-inflammatory pathways to address underlying causes of metabolic dysfunction rather than just symptoms. While CBD may not produce dramatic weight loss on its own, its ability to improve insulin sensitivity and reduce chronic inflammation could prove valuable for preventing diabetic complications and supporting long-term metabolic health.

The clinical evidence, while promising, remains limited by the relatively small scale and short duration of available studies. The mechanisms underlying cannabinoid effects on metabolism appear to involve complex interactions between central appetite regulation, peripheral metabolic modulation, and anti-inflammatory processes. This complexity suggests that successful therapeutic applications may require carefully designed combinations of cannabinoids rather than single-compound approaches.

Safety profiles of plant-derived cannabinoids appear generally favorable, particularly when compared to synthetic alternatives. However, the need for standardized, pharmaceutical-grade preparations cannot be overstated, as natural cannabis products exhibit significant variability that could affect both efficacy and safety.

6. FUTURE PROSPECTS

The future of cannabinoid-based metabolic medicine appears bright but will require sustained research effort, thoughtful regulation, and evidence-based clinical development to reach its full potential.

The most immediate priority involves conducting the large-scale, long-term clinical trials necessary to establish definitive efficacy and safety data for therapeutic cannabinoids. These studies must be designed to meet regulatory standards for drug approval while addressing the unique challenges of cannabis-derived medicines. Success in these trials could lead to the first approved cannabinoid medications specifically for metabolic conditions within the next decade.

The development of peripherally-restricted cannabinoid modulators represents an exciting technological frontier. These compounds aim to provide metabolic benefits while avoiding central nervous system effects, potentially offering the best of both worlds—therapeutic efficacy without psychiatric risks. Several such compounds are currently in early development, and their progress will be watched closely by the scientific community.

Personalized cannabinoid medicine may emerge as our understanding of individual variations in endocannabinoid system function improves. Just as genetic testing now guides dosing for some medications, future cannabinoid prescribing might be tailored to individual endocannabinoid profiles, genetic variations in cannabinoid metabolism, or specific metabolic dysfunction patterns.

The regulatory landscape will undoubtedly continue evolving, hopefully in directions that facilitate rather than hinder legitimate medical research and therapeutic development. The establishment of clear regulatory pathways for cannabis- derived medicines, appropriate quality standards, and rational scheduling policies will be crucial for translating research discoveries into patient benefits.

Perhaps most exciting is the potential for combination therapies that leverage cannabinoids' unique mechanisms alongside existing treatments. Rather than replacing current metabolic medications, cannabinoids might enhance their effectiveness while reducing side effects. A future patient with diabetes might receive a GLP-1 agonist for appetite control, metformin for insulin sensitivity, THCV for glucose regulation, and CBD for inflammation management—a comprehensive approach addressing multiple aspects of metabolic dysfunction simultaneously.

The growing understanding of endocannabinoid system complexity suggests that therapeutic opportunities extend far beyond CB1 and CB2 receptor modulation. Future treatments might target endocannabinoid synthesis enzymes, transport proteins, or degradation pathways, providing additional tools for fine-tuning metabolic function with greater precision and fewer side effects.

International collaboration will be essential for advancing this field. Cannabis research has been fragmented by varying legal restrictions across countries, but as regulations liberalize, opportunities for large-scale, multi-national studies will emerge. Such collaboration could accelerate research timelines while ensuring that findings apply across diverse populations and healthcare systems.

In conclusion, while significant challenges remain, cannabis-derived cannabinoids offer genuine promise for addressing the global epidemic of obesity and metabolic disease. The convergence of advancing scientific understanding, evolving regulatory frameworks, and growing clinical evidence suggests that cannabinoid-based metabolic treatments may transition from experimental curiosities to mainstream medical therapies within the coming decades. Success will require continued rigorous research, thoughtful regulation, and evidence-based clinical development—but the potential benefits for millions of patients struggling with metabolic disorders make these efforts well worthwhile.

The journey from ancient medicinal use of cannabis to modern precision cannabinoid therapeutics represents one of medicine's most fascinating stories of rediscovery and scientific validation. As we continue to unlock the secrets of the endocannabinoid system and develop safer, more effective ways to harness its therapeutic potential, we may find that nature provided us with powerful tools for metabolic health that we're only now learning to use properly.

REFERENCES

1. World Health Organization. Obesity and overweight fact sheet. Geneva: WHO; 2021.
2. Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-27.
3. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1):222S-225S.
4. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86.
5. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8(5):585-589.

6. Clark TM, Jones JM, Hall AG, et al. Theoretical explanation for reduced body mass index and obesity rates in cannabis users. Cannabis Cannabinoid Res. 2018;3(1):259-271.
7. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73-100.
8. Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1-37.
9. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423-431.
10. Radwan MM, Chandra S, Gul S, et al. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules. 2021;26(9):2774.
11. Parray HA, Yusufzai SI. Cannabidiol promotes browning in 3T3-L1 adipocytes. Mol Cell Biochem. 2016;416(1- 2):131-139.
12. McPartland JM, Duncan M, Di Marzo V, et al. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737-753.
13. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA. 2006;295(7):761-775.
14. Despres JP, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121-2134.
15. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010;376(9740):517-523.
16. Cinar R, Godlewski G, Liu J, et al. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance and hepatic steatosis. Diabetes. 2014;63(12):4032-4043.
17. Nagarkatti P, Pandey R, Rieder SA, et al. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-1349.
18. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
19. Turcotte C, Blanchet MR, Laviolette M, et al. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73(23):4449-4470.
20. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.
21. Cooper ZD, Craft RM, Carlisle SJF, et al. Challenges for clinical cannabis and cannabinoid research in the United States. J Pharmacol Exp Ther. 2022;380(1):114-125.
22. Cooper ZD, Bedi G, Ramesh D, et al. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046-2055.
23. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583.
24. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
25. Hooijmans CR, Rovers MM, de Vries RB, et al. SYRCLE's risk of bias tool for animal studies. PLoS One. 2014;9(3):e105657.
26. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol. 2007;36(1):92-101.
27. Wargent ET, Zaibi MS, Silvestri C, et al. The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. 2013;3:e68.
28. Rafailovska E, Geshkovska NM, Petreska Ivanovska T, et al. Unlocking the antidiabetic potential of CBD: in vivo insights into glucose regulation and hepatic enzyme modulation in diabetic rats. Pharmaceuticals (Basel). 2025;18(3):386.
29. Weiss L, Zeira M, Reich S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity. 2006;39(2):143-151.

30. Verty AN, McFarlane JR, McGregor IS, et al. The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology. 2011;36(7):1349-1358.
31. Klein C, Karanges E, Spiro A, et al. Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl). 2011;218(2):443-457.
32. Dörnyei G, Bekő K, Fehér A, et al. Role of the endocannabinoid system in metabolic control processes and in the pathogenesis of metabolic syndrome: a narrative review. Nutrients. 2023;15(10):2376.
33. Carai MA, Colombo G, Gessa GL, et al. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev. 2006;12(2):91-99.
34. Vidot DC, Prado G, Hlaing WM, et al. Metabolic syndrome among marijuana users in the United States: an analysis of National Health and Nutrition Examination Survey data. Am J Med. 2016;129(2):173-179.
35. Clark TM, Jones JM, Hall AG, et al. Theoretical explanation for reduced body mass index and obesity rates in cannabis users. Cannabis Cannabinoid Res. 2018;3(1):259-271.
36. Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777-1786.
37. Smith GL, Wang F, Gu WJ, et al. Weight loss and therapeutic metabolic effects of tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in overweight individuals: a randomized, double-blind, placebo-controlled study. Cannabis Cannabinoid Res. 2025;10(1):e25-e35.
38. Wiciński M, Fajkiel-Madajczyk A, Kurant Z, et al. The use of cannabidiol in metabolic syndrome—an evaluation of the current state of knowledge. Int J Mol Sci. 2023;24(15):12049.
39. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761-775.
40. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta- analysis of randomised trials. Lancet. 2007;370(9600):1706-1713.
41. Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry. 2009;21(2):163-171.
42. Riedel G, Fadda P, McKillop-Smith S, et al. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol. 2009;156(7):1154-1166.
43. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423-431.
44. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298-1305.
45. Nagarkatti P, Pandey R, Rieder SA, et al. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-1349.
46. Turcotte C, Blanchet MR, Laviolette M, et al. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73(23):4449-4470.
47. Ngueta G, Bélanger RE, Laouan-Sidi EA, et al. Cannabis use in relation to obesity and insulin resistance in the inuit population. Obesity (Silver Spring). 2015;23(2):290-295.
48. Alshaarawy O, Anthony JC. Cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replicates. Epidemiology. 2015;26(4):597-600.
49. Goodpaster KPS. Cannabis, weight, and weight-related behaviors. Curr Obes Rep.

2025;14(2):89-98.
50. Baral A, Eze IC, Blüher M, et al. Prevalence of metabolic syndrome among emerging adult cannabis users: findings from a nationally representative survey. Addict Behav Rep. 2024;19:100519.
51. Le Foll B, Trigo JM, Sharkey KA, et al. Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss? Med Hypotheses. 2013;80(5):564-567.
52. Cooper ZD, Bedi G, Ramesh D, et al. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046-2055.
53. Mendoza S, Presti C, Huff C, et al. The role of tetrahydrocannabivarin (THCV) in metabolic disorders: a mini-review of preclinical and clinical studies. AIMS Neuroscience. 2025;12(1):37-55.
54. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013;17(4):475-490.
55. Khan N, Pinzon-Herrera AF, Zhang X, et al. Peripherally selective CB1 receptor antagonist improves glucose tolerance and body weight in diet-induced obese mice. ACS Pharmacol Transl Sci. 2021;4(2):910-924.
56. Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod. 2017;103:103-131.
57. Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no "strain," no gain. Front Plant Sci. 2019;9:1969.
58. Hopkins MA, Lamm EV, Funk JL, et al. Targeting the endocannabinoid system for treatment of central sensitization and associated negative affect in chronic musculoskeletal pain: a narrative review. Life (Basel). 2024;14(4):518.
59. Skye Bioscience. Nimacimab Phase IIa clinical trial results. Clinical Trials Arena. 2024 Oct 6.
60. Soliman N, Haroutounian S, Hohmann AG, et al. Systematic review and meta-analysis of cannabinoids, cannabis- based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain. 2021;162(Suppl 1):S26-S44.
61. Cooper ZD, Craft RM, Carlisle SJF, et al. Challenges for clinical cannabis and cannabinoid research in the United States. J Pharmacol Exp Ther. 2022;380(1):114-125.
62. Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol. 2017;8:422.
63. Hossain MK, Dayem AA, Han J, et al. Medical cannabis: from research breakthroughs to shifting landscapes and the path forward for global acceptance. Phytother Res. 2024;38(8):4094-4125.
64. Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259.
65. Akurati S, Ayakannu T, Thompson J, et al. Exploring the endocannabinoid system's impact on obesity: a comprehensive review of molecular mechanisms and therapeutic implications. Curr Obes Rep. 2024;13(4):742-755.
66. Baratta F, Simiele M, Pignata I, et al. Cannabis for medical use: analysis of recent clinical trials. Front Pharmacol. 2022;13:888903.
67. Morales P, Isawi IH, Reggio PH. Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. Drug Metab Rev. 2018;50(1):74-93.
68. A glimpse into the pipeline of anti-obesity medication development: systematic review of clinical trials registered on ClinicalTrials.gov. Obes Sci Pract. 2024;10(5):e70009.